Keith Murphy is a serial life sciences entrepreneur and angel investor. He is the founding CEO of Viscient Biosciences, and was previously the founder, CEO and chairman of Organovo, the San Diego company advancing bio-printing technology.
Murphy has more than 20 years of experience in the life sciences industry, including 10 years at Amgen, here he spent four years as blobal operations leader in denosumab, the osteoporosis/bone cancer drug. Prior to Amgen, he played a central role at Alkermes, on the development team for their first approved product, Nutropin (hGH) Depot. He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management.
After starting Organovo in 2007, I spent much of the next decade as CEO seeking financing to advance our bioprinting technology.
Because I stepped out of an operational role early last... Read more »
© 2007-2019, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.